This telehealth company is expanding its platform to cover remote monitoring for pediatric patients with diabetes and other eligible conditions. Find out why one analyst says this company's stock is gathering momentum.
This telehealth company has signed a new contract with a Texas respiratory clinic that is expected to add 10,000 new patients to its iUGO platform by mid-2024. Read to see why one analyst believes this stock is a Buy.
This company has announced the general availability of its Linea IVT platform evaluation kits and the first kit shipment to an existing Linea IVT Template customer. It has also filed two provisional patent applications for its technologies to reduce the impurities and decrease manufacturing costs for mRNA therapies like some COVID-19 vaccines. Read to see what experts are saying about the stock.